stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Revenue
Kiniksa Pharmaceuticals International, plc's revenue for fiscal 2025 was $677.6M, up 60.1% from $423.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $946.0M. Over the past ten years it has ranged from $38.5M (fiscal 2021) to $677.6M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Kiniksa Pharmaceuticals International, plc ranks 23rd of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $677.6M | 60.09% |
| FY2024 | $423.2M | 56.60% |
| FY2023 | $270.3M | 22.74% |
| FY2022 | $220.2M | 471.24% |
| FY2021 | $38.5M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $286.0M | 17.39% |
| Jun 2026 | $243.6M | 13.69% |
| Mar 2026 | $214.3M | 6.01% |
| Dec 2025 | $202.1M | 11.76% |
| 18 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on KNSA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement